GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Recombinant human hyaluronidase PH20

Company
Halozyme Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Recombinant human hyaluronidase PH20 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05256225

    Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

    Not yet reported National Cancer Institute (NCI) 360 participants Est. completion 2027-10-31 414 sites
    Other conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
    View official trial listing →
  • Recruiting NCT NCT05418868

    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

    Not yet reported ViiV Healthcare 214 participants Est. completion 2027-06-08 3 sites
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT00705536

    Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

    Not yet reported Halozyme Therapeutics 26 participants Est. completion 2008-02 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00774800

    Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

    Not yet reported Halozyme Therapeutics 22 participants Est. completion 2009-03 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00803972

    Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

    Not yet reported Halozyme Therapeutics 42 participants Est. completion 2009-08-28 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT00807963

    Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

    Not yet reported Halozyme Therapeutics 31 participants Est. completion 2009-09-21 1 site Stand-alone
    Other conditions: Risk Factors for or a Diagnosis of Osteoporosis
    View official trial listing →
  • Completed NCT NCT00883558

    Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

    Not yet reported Halozyme Therapeutics 48 participants Est. completion 2010-04 8 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00916357

    Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Halozyme Therapeutics 23 participants Est. completion 2009-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00979875

    A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

    Not yet reported Halozyme Therapeutics 14 participants Est. completion 2010-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01194245

    Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

    Not yet reported Halozyme Therapeutics 135 participants Est. completion 2011-08 19 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT01194258

    Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

    Not yet reported Halozyme Therapeutics 132 participants Est. completion 2011-08 22 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type II
    View official trial listing →
  • Completed NCT NCT01275131

    Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

    Not yet reported Halozyme Therapeutics 45 participants Est. completion 2011-12 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01526733

    Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

    Not yet reported Halozyme Therapeutics 25 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT02346370

    A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

    Not yet reported Halozyme Therapeutics 16 participants Est. completion 2016-11-14 8 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT03446040

    An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

    Not yet reported, Not yet reported Bristol-Myers Squibb 92 participants Est. completion 2024-08-29 16 sites Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT03538626

    Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 33 participants Est. completion 2022-08-29 1 site Stand-alone
    Other conditions: HIV Antibodies
    View official trial listing →
  • Completed NCT NCT03656718

    A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

    Not yet reported, Not yet reported Bristol-Myers Squibb 139 participants Est. completion 2024-09-12 36 sites
    Other conditions: Neoplasms by Site
    View official trial listing →
  • Withdrawn NCT NCT04058964

    Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

    Not yet reported M.D. Anderson Cancer Center Est. completion 2022-10-31 1 site Stand-alone
    Other conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04073589

    Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

    Not yet reported argenx 33 participants Est. completion 2019-09-26 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04484337

    Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

    Not yet reported ViiV Healthcare 138 participants Est. completion 2023-05-05 5 sites Stand-alone
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT05291520

    A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

    Not yet reported ViiV Healthcare 24 participants Est. completion 2023-04-10 1 site
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT05396742

    Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

    Not yet reported Alexion Pharmaceuticals, Inc. 49 participants Est. completion 2019-05-21 1 site
    Other conditions: Healthy
    View official trial listing →
  • Not yet recruiting NCT NCT07742527

    A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

    Not yet reported GlaxoSmithKline 22 participants Est. completion 2030-03-18 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.